ZURICH (Reuters) - Swiss drugmaker Roche said on Thursday initial data on a protease inhibitor, danoprevir, is encouraging against Hepatitis C.
"The high sustained viral response rates and encouraging safety data show danoprevir is potent and well-tolerated," Roche development head Hal Barron said in a statement.
"Roche's HCV portfolio includes multiple investigational drugs with different modes of action, allowing us to develop tailored treatments that aim to address the future needs of patients with chronic hepatitis C," Barron said.
(Reporting By Katharina Bart)
Trending On Reuters
Sweatworking, the growing practice of meeting clients for a walk, a run or a fitness class, is elbowing networking out of bars and restaurants and into boutique fitness studios. Full Article
Prognosis unclear for daughter of late singer Whitney Houston - lawyer Full Article
EU ministers discuss migrant crisis as shipwrecked bodies brought ashore Full Article